Dual intervention on the gut and skin microbiota attenuates facial cutaneous aging

The gut and skin microbiota are microbial barriers, resisting harmful foreign microorganisms and maintaining internal homeostasis. Dysbiosis of the gut and skin microbiota is involved in aging progression. However, interventions targeting facial skin wellness taking into account the gut-skin axis are scarce. In this study, the impact of an eight-week intervention with oral (O), topical (T), and both oral and topical (OT) xylo-oligosaccharides (XOS) by regulating gut and skin microbiota on facial cutaneous aging was investigated in a double-blind placebo-controlled trial in females. An increase in the proportion of participants with skin rejuvenation was observed, along with a significant reduction in facial pores after OT intervention. The reduction of cutaneous Cutibacterium by OT intervention was greater than that in the O and T groups. These interventions can change the skin microbial structure. Intestinal Bifidobacterium was enriched only by dual treatment with oral and topical XOS. Function prediction analysis revealed a decrease in K02770 encoding fructose-1-phosphate kinase involved in de novo lipid synthesis from fructose with dual intervention, suggesting that inhibition of lipophilic Cutibacterium may contribute to reducing facial pores. Overall, the dual XOS intervention approach is most effective for improving both gut and skin microbiota, as well as facial skin aging.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:15

Enthalten in:

Food & function - 15(2024), 8 vom: 22. Apr., Seite 4246-4261

Sprache:

Englisch

Beteiligte Personen:

Zhang, Liujing [VerfasserIn]
Yu, Shun [VerfasserIn]
Guan, Yin [VerfasserIn]
Wang, Dan [VerfasserIn]
Yang, Ju [VerfasserIn]
Li, Jingling [VerfasserIn]
Zhao, Wei [VerfasserIn]
Zhang, Feng [VerfasserIn]

Links:

Volltext

Themen:

Journal Article
Oligosaccharides
Randomized Controlled Trial

Anmerkungen:

Date Completed 23.04.2024

Date Revised 24.04.2024

published: Electronic

Citation Status MEDLINE

doi:

10.1039/d3fo05473j

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM370156374